TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma: Chimeric antigen receptor T (CAR-T) cells directed against CD30 have been developed and are being explored in a phase II trial (NCT04083495) in patients with R/R CD30+ PTCL.